Sheep Factor VIII:C Polyclonal Antibody | anti-FVIII antibody

Sheep anti-human Factor VIII, Affinity-Purified IgG

Cat. Num. AAA512052

• Purity: Affinity purified IgG.; Vial containing ml of IgG purified by affinitychromatography on immobilized F.VIII. Total protein is 0.5 mg.
• Synonyms: Factor VIII:C; Polyclonal Antibody; Sheep anti-human Factor VIII; Affinity-Purified IgG; human; anti-FVIII antibody

• Host: Sheep
• Clonality: Polyclonal
• Specificity: This antibody is specific for F.VIII as demonstrated by immunoelectrophoresis and ELISA.
• Purity/Purification: Affinity purified IgG.; Vial containing ml of IgG purified by affinitychromatography on immobilized F.VIII. Total protein is 0.5 mg.
• Form/Format: Affinity-Purified IgG, clear liquid.
• Concentration: APIgG concentration is mg/ml, determined by absorbance using an extinction coefficient (E1%280) of 13.4. (varies by lot)

• Application Notes: Suitable as a source of antibodies to Factor VIII.
• Immunogen: Human F.VIII (F.VIII:C) purified from concentrate.
• Buffer: 10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.
• Neutralizing Activity: XXXX Bethesda Units/ml IgG against normal plasma (Kasper CK et al, Thromb Diath Haemorrh 34:869, 1975). One Bethesda unit/ml is defined as the amount of inhibitor that resulted in 50% residual F.VIII activity after 2 hours at 37 degree C.
• Preparation and Storage: Store between -10 and -20 degree C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.

Related Product Information for anti-FVIII antibody

Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of F.VIII ranging in size from 200-280 kDa. The F.VIII is stabilized by association with von Willebrand Factor to form a F.VIII-vWF complex required for the normal survival of F.VIII in vivo (t1/2 of 8-12 hours). F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, F.VIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay. Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of F.VIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a F.VIII protein that is partially or totally inactive. The production of neutralizing antibodies to F.VIII also occurs in 5-20% of Hemophiliacs 1-3.

References

1. Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
2. Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
3. Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostas. 61:161-165, 1989.

NCBI and Uniprot Product Information

• NCBI GI #: 4262857
• NCBI Accession #: AAD15005.1
• NCBI GenBank Nucleotide #: S81579.1
• NCBI Official Full Name: factor VIII
• NCBI Official Symbol: FVIII